Codexis (CDXS) Insider Esther Martinborough Buys 66,350 Shares
Insider Esther Martinborough bought a significant number of shares in Codexis, Inc., signaling support for the company's future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Esther Martinborough bought 66,350 shares of Codexis, Inc. ($CDXS) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDXS is down 8.5% after 1 week, down 9.7% after 1 month and down 50.0% to date (from the $2.48 close on Jun 17, 2026).
CDXS
Codexis, Inc.
Key Points
- On June 17, 2026, Esther Martinborough purchased 66,350 shares of Codexis, Inc. at a price of $2.57 each, totaling a transaction valued at approximately $170,000.
- Codexis, Inc. recently reported a revenue of $77.7 million, but it has faced challenges with a net margin of -39.6%.
- Analysts maintain a 'buy' recommendation for Codexis, with a target price of $8.00 as of August 17, 2026.
Get $CDXS trade alerts by text
We text you when insiders, Congress or big funds trade $CDXS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Codexis, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Codexis, Inc.
On June 17, 2026, Esther Martinborough bought 66,350 shares of Codexis, Inc. (CDXS) on the NasdaqGS for about $170,000, as the stock traded at $2.57. This purchase adds to a wave of insider activity at the company, with several other executives making similar buys on the same day.
Collective Insider Confidence
Along with Martinborough, insiders De Vre Raymond, Cynthia Collins, Dilly Stephen George, Rahul Singhvi, David Smith, and Stewart Parker each acquired 66,350 shares on June 17, 2026. This collective action may reflect a strong belief in Codexis's future direction, especially as the company continues to develop its biotechnology solutions.
How Codexis, Inc. Stock Has Traded
Currently, Codexis shares are trading at $2.57, which is above its 52-week low of $0.96 but below its high of $2.98. The stock's recent performance has shown volatility, and the insider purchases may indicate a strategic alignment among the company's leadership.
Analysts Set New Price Targets
On August 17, 2026, Piper Sandler maintained an 'Overweight' rating for Codexis, with a target price of $8.00, down from $9.00. This suggests that analysts see potential upside for the stock, even as the company navigates its current financial challenges.
What Codexis, Inc. Does
Codexis, Inc. specializes in technology solutions for manufacturing therapeutics, focusing on enzyme development. It operates in a competitive biotechnology industry and is headquartered in Redwood City, California.
Future Watch
Investors will be looking for Codexis's next earnings report, scheduled for November 5, 2026. As a reminder, the recent insider trades reflect past decisions and may not represent current positions. Further filings could provide more insights into the company's direction and performance.
Related Filing Alerts
Source: Esther Martinborough's Form 4 filing on $CDXS (Jun 17, 2026). Find the original filing: CDXS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts